Metaxalone is a drug owned by Primus Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 29, 2039. Details of Metaxalone's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11918559 | Reduced dose metaxalone formulations |
Jul, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Metaxalone's patents.
Latest Legal Activities on Metaxalone's Patents
Given below is the list of recent legal activities going on the following patents of Metaxalone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification
Critical | 05 Mar, 2024 | US11918559 |
| Recordation of Patent Grant Mailed
Critical | 05 Mar, 2024 | US11918559 |
| Patent Issue Date Used in PTA Calculation
Critical | 05 Mar, 2024 | US11918559 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918559 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918559 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918559 |
| Email Notification
Critical | 14 Feb, 2024 | US11918559 |
| Issue Notification Mailed
Critical | 14 Feb, 2024 | US11918559 |
| Dispatch to FDC | 05 Feb, 2024 | US11918559 |
| Application Is Considered Ready for Issue
Critical | 05 Feb, 2024 | US11918559 |
US patents provide insights into the exclusivity only within the United States, but
Metaxalone is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Metaxalone's family patents as well as insights into
ongoing legal events
on those patents.
Metaxalone's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Metaxalone's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 29, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Metaxalone Generic API suppliers:
Metaxalone is the generic name for the brand Metaxalone. 8 different companies have already filed for the generic of Metaxalone, with Sciegen Pharms Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Metaxalone's generic
Alternative Brands for Metaxalone
There are several other brand drugs using the same active ingredient (Metaxalone) as Metaxalone. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| King Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metaxalone, Metaxalone's active ingredient. Check the complete list of approved generic manufacturers for Metaxalone
About Metaxalone
Metaxalone is a drug owned by Primus Pharmaceuticals Inc. Metaxalone uses Metaxalone as an active ingredient. Metaxalone was launched by Primus Pharms in 2015.
Approval Date:
Metaxalone was approved by FDA for market use on 01 June, 2015.
Active Ingredient:
Metaxalone uses Metaxalone as the active ingredient. Check out other Drugs and Companies using Metaxalone ingredient
Dosage:
Metaxalone is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 640MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |